The content on or accessible through Medpedia.com is for informational purposes only. Medpedia is not a substitute for professional advice or expert medical services from a qualified health professional. Read more

Nitisinone

Lead Editors

(Become a Lead Editor)

There are currently no Lead Editors of this article.

Ask a Question on This Topic

Important Resources for Nitisinone:

Nitisinone is a prescription drug used in the treatment of the genetic disease hereditary tyrosinemia type 1 (HT-1). In this disorder, the body is unable to metabolize the amino acid tyrosine. The accumulation of toxic compounds in individuals with this disorder often causes kidney and liver damage. Nitisinone was originally developed as a pesticide. The Food and Drug Administration approved nitisinone on January 18, 2002. Nitisinone is marketed as Orfadin by Swedish Orphan International.

Contents

Uses

Nitisinone is used to treat HT-1 in addition to dietary restriction of tyrosine and phenylalanine intake.

How Nitisinone is Taken

Nitisinone is available in capsules of 2 mg, 5 mg, and 10 mg. The recommended initial dosing is 1 mg/kg body weight daily, divided equally into one morning dose and one evening dose. The effect of food on the absorption of nitisinone is not known. Taking the doses at least one hour before a meal reduces the risk of food hindering the absorption. A maximum dose of 2 mg/kg/day may be needed, especially in infants. The capsule can be broken open and the liquid applied to food for children who cannot take the capsule.

How Nitisinone Works

HT-1 is caused by a deficiency in fumarylacetoacetase (FAH), the final enzyme in the pathway that breaks down tyrosine. Nitisinone inhibits 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of FAH in this pathway. This inhibition prevents the accumulation of intermediate compounds in the pathway, which are toxic to the liver and kidneys.

How the Body Affects Nitisinone

Peak circulating levels of nitisinone are reached 3 hours after ingestion of the capsule and within 15 minutes of taking the liquid. The half-life of nitisinone, the time needed for the concentration of the drug in the blood to be reduced by half, is approximately 58 hours. The metabolism and excretion of nitisinone in humans are not known.

Side Effects

The most common side effects of nitisinone, which occurred in more than 1% of patients in clinical trials, were the following:

  • liver tumors
  • liver failure
  • inflammation of the membrane on the cornea and other corneal issues
  • hypersensitivity to light
  • eyelid inflammation
  • eye pain
  • cataracts
  • low blood platelet counts
  • low white blood cell count
  • porphyria
  • nose bleed
  • itching
  • skin disorders (redness, scaling, or dry skin)
  • hair loss

Risks and Precautions

Dietary restriction of tyrosine and phenylalanine intake is absolutely necessary in patients with HT-1, even those taking nitisinone. Elevated Tyrosine levels increase the risk of eye and skin problems as well as nervous system complications (mental retardation and developmental delay).

Drug Interactions

No drug interaction studies have been conducted to date.

Research

People with HT-1 under six months of age have a four-year survival probability of 60%. The four-year survival probability in these patients treated by dietary restriction and nitisinone is 94%.[1]

References

  1. Food and Drug administration Web site. ORFADIN capsules PDF

External Links

FDA: Patient Information Sheet

Drugs.com

To suggest changes to this page, you must create an account on Medpedia.

The content on or accessible through Medpedia.com is for informational purposes only. Medpedia is not a substitute for professional advice or expert medical services from a qualified health professional. Read more